First-in-class treatments or unmet needs in epilepsy
Our Mission
To develop paradigm changing, first in class treatments for:
Acute prevention of predictable seizures using non-benzodiazepine rapid intranasal treatment
Prevention of epilepsy after traumatic brain injury and stroke
Treatment of neonatal seizures
About PrevEp
PrevEp was founded by world renown epilepsy experts, including the discoverers of Keppra and of ezogabine/retigabine. The founders combine deep expertise in basic science, drug development and clinical trials in epilepsy. The intimate collaboration between preclinical and clinical team members allows rapidly translation of preclinical discoveries into clinic.
Click on picture for full bio
Pavel Klein
Chief Executive Officer, Co-founder
Wolfgang Löscher
Chief Scientific Officer, Co-founder
Chris Rundfeldt
Chief Operation Officer, Co-founder
Detlev Boison
Alexander Rotenberg
Biomarker Development, Co-founder
Matthias Koepp
VP, Product Development, Co-founder
Eugen Trinka
VP, Clinical Trials, Co-founder
Strategy
INTRANASAL SELETRACETAM FOR PREEMPTIVE TREATMENT OF PREDICTABLE SEIZURE.
An intranasal seletracetam spray which shifts treatment paradigm to on-demand preemptive treatment to prevent predictable seizures:
- Reflex Epilepsies/seizures: lead indication;
rare disease, orphan potential - Triggered seizure, ~50% of all seizures with blockbuster potential
- Preemptive treatment for predicted seizures: as the only treatment solution for the rapidly developing seizure prediction devices. Blockbuster potential
- Potent, rapid-onset, portable, safe,
non-sedating and non-addictive, non-benzodiazepine
Intranasal seletracetam is the only non-benzodiazepine also developed for treatment of acute seizure rescue therapy, further expansion
EPILEPSY PREVENTION BY NETWORK PHARMACOLOGY. Epileptogenesis is a complex process that is unlikely to be arrested by a single drug. PrevEp leverages recent discoveries in network pharmacology to design combination therapies that target a multitude of epileptogenic mechanisms, in the earliest stages after brain injury. Our lead combinations of safe FDA-cleared molecules are well-tolerated and have proven to block epileptogenesis in predictive rodent models.
NEONATAL SEIZURE TREATMENT BY INTRAVENOUS TOPIRAMATE. Neonatal seizures increase mortality and risk of lifelong brain damage. A safe and FDA-approved drug, topiramate suppresses neonatal seizures when other anti-seizure medications fail, but was not available in injectable form. PrevEp developed a novel intravenous topiramate formulation with orphan drug designation for neonatal seizure treatment
Advisory Board
Our company concept is supported by leading epilepsy ambassadors
Jacqueline A. French, M.D.
Professor of Neurology and Director of clinical trials at NYU Langone‘s Comprehensive Epilepsy Center; Chief Scientific Officer, Epilepsy Foundation
Michael A. Rogawski, M.D., PhD.
Professor of Neurology and Pharmacology, Director of Institute for Neurotherapeutics, University of California, Davis
Elizabeth Garofalo, M.D.
Principal for EAG Pharma Consulting LLC; former SVP, Novartis Parmaceutical Coorporation
Annamaria Vezzani, Ph.D.
Professor of Neuroscience, Mario Negri Institute, Milan, Italy
Henrik Klitgaard, Ph.D.
Previous Vice President, Neurosciences Therapeutic Area, UCB Biopharma
Enrique Carrazana, M.D.
SVP, strategic development, Neurelis
